Elicio Therapeutics – AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk G12D- or G12R- mutated pancreatic and colorectal cancer
| DATE: | June 12, 2023 |
|---|---|
| TIME: | 8:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Elicio Therapeutics – AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk G12D- or G12R- mutated pancreatic and colorectal cancer
Presenter: Dr. Shubham Pant